These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 6613833)

  • 21. Malignant ventricular arrhythmia in the Wolff-Parkinson-White syndrome during amiodarone treatment.
    Perticone F; Cuda G; Spadea F; Pintaudi C; Tropea R
    Clin Cardiol; 1987 Aug; 10(8):477-80. PubMed ID: 3621696
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of drugs in the Wolff-Parkinson-White syndrome. Importance of initial length of effective refractory period of the accessory pathway.
    Wellens HJ; Bär FW; Dassen WR; Brugada P; Vanagt EJ; Farré J
    Am J Cardiol; 1980 Oct; 46(4):665-9. PubMed ID: 7416026
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Amiodarone in long term management of refractory cardiac tachyarrhythmias.
    Lubbe WF; Mercer CJ; Roche AH; Lowe JB
    N Z Med J; 1981 Jan; 93(676):31-5. PubMed ID: 6940024
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of isoproterenol on the anterograde refractory period of the accessory pathway in patients with the Wolff-Parkinson-White syndrome.
    Wellens HJ; Brugada P; Roy D; Weiss J; Bär FW
    Am J Cardiol; 1982 Jul; 50(1):180-4. PubMed ID: 7090999
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of amiodarone in the Wolff-Parkinson-White syndrome. A clinical and electrophysiological study.
    Rasmussen V; Berning J
    Acta Med Scand; 1979; 205(1-2):31-7. PubMed ID: 367085
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Multiple circus movement tachycardias with multiple accessory pathways.
    Heddle WF; Brugada P; Wellens HJ
    J Am Coll Cardiol; 1984 Jul; 4(1):168-75. PubMed ID: 6736443
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Electrophysiologic effects of amiodarone in Wolf-Parkinson-White syndrome].
    Touboul P; Porte J; Huerta F; Delahaye JP
    Arch Mal Coeur Vaiss; 1976 Aug; 69(8):855-63. PubMed ID: 823923
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Control of tachyarrhythmias associated with Wolff-Parkinson-White syndrome by amiodarone hydrochloride.
    Rosenbaum MB; Chiale PA; Ryba D; Elizari MV
    Am J Cardiol; 1974 Aug; 34(2):215-23. PubMed ID: 4843156
    [No Abstract]   [Full Text] [Related]  

  • 29. Usefulness of programmed stimulation in predicting efficacy of propafenone in long-term antiarrhythmic therapy for paroxysmal supraventricular tachycardia.
    Manz M; Steinbeck G; Lüderitz B
    Am J Cardiol; 1985 Oct; 56(10):593-7. PubMed ID: 4050693
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The use of intravenous amiodarone in patients with atrial fibrillation and Wolff-Parkinson-White syndrome.
    Ren J; Yang Y; Zhu J; Wu S; Wang J; Zhang H; Shao X
    Pacing Clin Electrophysiol; 2021 Jan; 44(1):35-43. PubMed ID: 33118640
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Atrial and ventricular vulnerability in a patient with the Wolff-Parkinson-White syndrome.
    Peters RW; Gonzalez R; Scheinman MM
    Pacing Clin Electrophysiol; 1981 Jan; 4(1):17-22. PubMed ID: 6171787
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Use of intracardiac recordings to determine the site of drug action in paroxysmal supraventricular tachycardia.
    Jackman WM; Friday KJ; Fitzgerald DM; Yeung-Lai-Wah JA; Lazzara R
    Am J Cardiol; 1988 Dec; 62(19):8L-19L. PubMed ID: 3059792
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Clinical experience with propafenone in paroxysmal supraventricular reciprocating tachycardias].
    Furlanello F; Vergara G; Dal Forno P; Disertori M; Inama G
    G Ital Cardiol; 1984 May; 14(5):379-80. PubMed ID: 6468821
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of verapamil on the electrophysiologic properties of the accessory pathway in patients with the Wolff-Parkinson-White syndrome.
    Harper RW; Whitford E; Middlebrook K; Federman J; Anderson S; Pitt A
    Am J Cardiol; 1982 Dec; 50(6):1323-30. PubMed ID: 7148709
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of intravenous diltiazem administration in patients with inducible tachycardia.
    Waleffe A; Hastir F; Kulbertus HE
    Eur Heart J; 1985 Oct; 6(10):882-90. PubMed ID: 4076199
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mechanism of termination of re-entrant paroxysmal supraventricular tachycardia in WPW syndrome by IV amiodarone.
    Khalilullah M; Gambhir DS; Bahl VK; Ahmed M; Balachander J; Gupta R
    Indian Heart J; 1985; 37(1):18-22. PubMed ID: 4007912
    [No Abstract]   [Full Text] [Related]  

  • 37. [Verapamil in the study and treatment of supraventricular tachycardias, with special reference to pre-excitation].
    Krikler DM
    Minerva Med; 1975 May; 66(39):1914-22. PubMed ID: 236526
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of isoproterenol and amiodarone and the role of exercise in initiation of circus movement tachycardia in the accessory atrioventricular pathway.
    Brugada P; Facchini M; Wellens HJ
    Am J Cardiol; 1986 Jan; 57(1):146-9. PubMed ID: 3942059
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pre-excitation syndrome in infants and children. Effect of digoxin, verapamil, and amiodarone.
    Shahar E; Barzilay Z; Shem-Tov AA; Shohet I; Frand M
    Arch Dis Child; 1983 Mar; 58(3):207-11. PubMed ID: 6838251
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical and electrophysiologic characteristics in patients with Wolff-Parkinson-White pattern.
    Antunes E; da Silva N; Catarino C; Serra J; Galrinho A; Ferreira R; Quininha J; Gracias R; Rato JA
    Rev Port Cardiol; 1993 Apr; 12(4):333-6. PubMed ID: 8512728
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.